New Posts New Posts RSS Feed - disappointing TNBC trial results
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

disappointing TNBC trial results

 Post Reply Post Reply
Author
SagePatientAdvocates View Drop Down
Senior Advisor
Senior Advisor
Avatar

Joined: Apr 15 2009
Status: Offline
Points: 4746
Post Options Post Options   Thanks (0) Thanks(0)   Quote SagePatientAdvocates Quote  Post ReplyReply Direct Link To This Post Topic: disappointing TNBC trial results
    Posted: Jan 10 2022 at 11:45am
Dear TNBC family,


Hope you all can open it...

Here is a brief summary based on a statement from Dr. Ingrid Mayer an excellent TNBC specialist at Vanderbilt i Nashville, TN.

– Should discourage use of adjuvant platinum in residual TNBC post-neoadjuvant chemo, she says

by Jeff Minerd , Contributing Writer, MedPage Today January 4, 2022

This Reading Room is a collaboration between MedPage Today® and:

 Medpage Today

Platinum-based agents have been used as adjuvant therapy for patients with residual triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy, based on clinical trial data showing improved pathological complete response (pCR) rates. Newer data, however, should discourage this practice, scientists said.

The ECOG-ACRIN EA1131 trial found that platinum-based chemotherapy did not extend invasive disease-free survival compared with capecitabine in patients with TNBC residual disease following neoadjuvant chemotherapy, regardless of the cancer subtype, and was associated with more severe toxicity.
..............

with my love to all here,


Steve

I am a BRCA1+ grandson, son and father of women affected by breast/oc-my daughter inherited mutation from me, and at 36, was dx 2004 TNBC I am a volunteer patient advocate with SAGE Patient Advocates
Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 12.01
Copyright ©2001-2018 Web Wiz Ltd.